At a glance
- For eligible Medicare Part D beneficiaries, the price is $50 a month — a number that belongs in a retirement plan.
- The expansion arrives as GLP-1 use has quadrupled since 2024.
- KFF says covered drugs are FDA-approved for weight management in adults with a body mass index of 30 or higher.
The GLP-1 Bridge program starts July 1. For eligible Medicare Part D beneficiaries, the price is $50 a month — a number that belongs in a retirement plan. KFF puts the eligible population at roughly 4 million people. The coverage runs to the end of 2027 and gives them a Medicare route to Wegovy, Zepbound and Foundayo for obesity. Financial Planning first reported the terms.
The expansion arrives as GLP-1 use has quadrupled since 2024. Gallup finds 11% of Americans now take the injectables for weight loss. Two years earlier, the share was 3%. The drugs were developed for Type 2 diabetes, but they have shown benefits beyond glucose control: lower risk of heart attacks and strokes in obese patients with heart disease, lower blood pressure, and help with addiction. High prices kept many retirees off them, and Medicare had no pathway to cover the drugs for obesity alone.
The bridge is narrow. KFF says covered drugs are FDA-approved for weight management in adults with a body mass index of 30 or higher. Adults with a BMI of 27 can qualify if they also have an obesity-related condition. A physician must sign off before Medicare approves the prescription. Beneficiaries who filled any GLP-1 under Part D in 2026 are excluded. The National Council on Aging notes that not everyone qualifies, and the sign-off step adds friction even for those who do.
The $50 copay does not count toward the deductible or the annual out-of-pocket cap. Starting a GLP-1 therefore does not move a retiree closer to catastrophic coverage. For budgeting, it is a standalone cost line, not a lever on total drug spending.
A $170,000 backdrop
The coverage arrives as retirement healthcare cost estimates keep climbing. Fidelity's 2025 estimate covered premiums, deductibles and drug purchases. It put the total over a retirement at more than $170,000. Against that, the $50 copay is real money, but the clinical case matters more. Dr. Dennis Weaver, chief clinical officer at Pearl Health, told Financial Planning that treating obesity as a chronic condition has downstream effects: fewer heart attacks, strokes and blood-pressure complications, and those effects can save thousands of dollars in long-run healthcare spending.
The program runs only through 2027. The eligibility condition, no prior GLP-1 fill under Part D in 2026, looks like a way to cap the budget hit from the drug class's popularity spike. Advisors planning past the expiration date need two scenarios: the $50-copay version, and a post-bridge version where the drugs return to full out-of-pocket cost. That second version tests whether a client can stay on the medication without wrecking the healthcare line.
For a client who meets the BMI criteria, has not filled a GLP-1 under Part D this year, and can get a physician to sign off, the window is now. The rest is plan math. Add $50 a month to the healthcare spending line. Mark the calendar for 2027, when the bridge either becomes permanent or the $50 copay goes away.
Reported by the Tax & estate planning desk from Financial Planning. Published . Corrections